A member of President Donald Trump’s transition team, Makan Delrahim, will be nominated to head the US Justice Department’s Antitrust Division, the White House said on Monday.
He reportedly worked as a lobbyist for Anthem from July 2015 to September 2016 on antitrust issues associated with the insurer’s proposed $54 billion acquisition of Cigna, according to the International Business Times.
Delrahim is expected to move to the Justice Department after finishing up in the White House counsel’s office, where he has worked to steer Supreme Court nominee Neil Gorsuch through the Senate confirmation process.
The Senate must vote to confirm Delrahim once the nomination is formalized.
As the proposed chief of the Antitrust Division, Delrahim would review corporate mergers at a time when many investors and corporate executives are anticipating a more relaxed view of deal-making after years of tough oversight by the administration of former President Barack Obama.
Antitrust experts who have followed Delrahim’s career have said that when it comes to merger approvals he would follow in the footsteps of a former boss, Hewitt Pate, who was assistant attorney general of antitrust from 2003 to 2005. Delrahim was Pate’s deputy, specializing in international antitrust.
Full Content: Healthcare Finance news
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Meta Begins Defense After FTC Concludes Case in Landmark Antitrust Trial
May 15, 2025 by
CPI
UK Data Bill Still No Closer to Passage As Parliamentary ‘Ping-Pong’ Drags On
May 15, 2025 by
CPI
Regeneron Pharmaceuticals Awarded $271.2M in Damages Against Amgen
May 15, 2025 by
CPI
FTC Chair Proposes 15% Staff Reduction Amid Budget Constraints
May 15, 2025 by
CPI
UK Urges Antitrust Watchdog to Prioritize Growth and Clarity in Business Regulation
May 15, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Healthcare Antitrust
May 14, 2025 by
CPI
Healthcare & Antitrust: What to Expect in the New Trump Administration
May 14, 2025 by
Nana Wilberforce, John W O'Toole & Sarah Pugh
Patent Gaming and Disparagement: Commission Fines Teva For Improperly Protecting Its Blockbuster Medicine
May 14, 2025 by
Blaž Višnar, Boris Andrejaš, Apostolos Baltzopoulos, Rieke Kaup, Laura Nistor & Gianluca Vassallo
Strategic Alliances in the Pharma Sector: An EU Competition Law Perspective
May 14, 2025 by
Christian Ritz & Benedikt Weiss
Monopsony Power in the Hospital Labor Market
May 14, 2025 by
Kevin E. Pflum & Christian Salas